AI holds promise: but we still need good science at the core of breast cancer diagnostics
Cancer diagnostics is a constantly evolving landscape, many in this field are working tirelessly to improve on the tools available. And rightly so: breast cancer diagnostics haven't significantly changed in over half a century.
AI is getting lots of attention, including in the healthcare world. The Health Foundation recently released a long-read on AI in healthcare. This highlights the promise but also the challenges: include the extensive effort needed to develop specific diagnostic tools, addressing bias, and ensuring thorough validation. As well as the environmental and financial issues, for example, digital slide storage.
AI could be one tool to assist pathologists in the future, but with the high implementation costs and questionable learning techniques, it’s not a reliable method that can make a difference right now.
More is needed to support the pathology workforce
AI will never replace the good science needed at the core of breast cancer diagnostics.
However, we know that MammaTyper® can improve the accuracy, reproducibility and efficiency of breast cancer diagnostics. This will help tackle workforce issues such as pathologist shortages and testing backlog, as MammaTyper® speeds up the diagnostic process.
Recommended by LinkedIn
MammaTyper® is a tool that can be implemented now
It is also the only assay of its type that is backed by extensive research, showing that it is a viable companion and even alternative to IHC.
With a simple kit that allows quantitative mRNA assessment of 4 biomarkers recommended by the ESMO guidelines (ERBB2, ESR, PgR, Ki-67), we offer a reliable, standardised, robust and easily reproducible analysis in any laboratory.
The linearity of the assay allows easy identification of samples with low or reduced HER2 expression and/or amplification, thus reducing the percentage of under- or over-treatment.
AI will inevitably become part of that mix in the future, but MammaTyper® is a tool that is ready to go to labs now. Running on existing equipment and with the research to back it up.
Get in touch to discuss how MammaTyper®can help info@cercabiotech.com